Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ANRS, Emerging Infectious Diseases
With
University of Bordeaux
PACCI Program
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients over 18 years of age.
With SARS-CoV-2 infection confirmed by specific PCR.
With clinical manifestations of the infection, such as fever or cough, or otolaryngologic (ORL) signs or respiratory difficulties, that started less than 7 days ago.
COVID-19 specific treatment-naive.
Women of childbearing age should accept the use of mechanical contraception during the study period.
Informed consent signed by the patient.
You may not be if
Severe form of infection requiring oxygen therapy \> 4l/min to achieve oxygen saturation \> 94%.
Patient whose weight is \< 35kg.
Pharmacological investigation contraindicating the introduction of a CYP450 inhibitor, in particular the CYP3A4 isoform.
Known hypersensitivity to lopinavir, ritonavir, telmisartan, atorvastatin or their excipients.
HIV-infected patient without treatment or treated with protease inhibitors (lopinavir, darunavir, atazanavir).
Ongoing exposure to statins.
Contraindications to the use of statin:
CPK \> 5N, history of rhabdomyolysis or myopathies, increased risk when atorvastatin is administered with strong CYP3A4 inhibitors or transport proteins (cyclosporin, telithromycin, clarithromycin, delavirdine, stiripentol, ketoconazole, voriconazole, itraconazole, posaconazole, letermovir, erythromycin, diltiazem, verapamil, fluconazole).
Ongoing exposure to sartans.
Contraindications to the use of telmisartan:
patient on angiotensin-converting enzyme (ACE) inhibitors, aliskiren or other angiotensin receptor blockers (ARB).
Curatorship or guardianship.
Pregnancy or breastfeeding.
Dementia or any other condition that prevents informed consent.
Any reason that, at the discretion of the investigator, would compromise patient safety and cooperation in the trial.
Clareo Health | Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial
